Anuh Pharma Ltd Valuation Shifts Signal Improved Price Attractiveness Amid Mixed Market Returns

Valuation Metrics Reflect Improved Price Attractiveness

As of 24 Feb 2026, Anuh Pharma’s P/E ratio stands at 17.61, a figure that positions the company favourably against many of its peers in the Pharmaceuticals & Biotechnology sector. This is a significant improvement from previous levels, contributing to the upgrade of its valuation grade from fair to attractive. The P/BV ratio of 2.25 further supports this positive re-rating, indicating that the stock is trading at a reasonable premium to its book value relative to sector norms.

Other valuation multiples such as EV to EBIT (15.56) and EV to EBITDA (12.55) also suggest a balanced valuation, especially when contrasted with more expensive peers like Shukra Pharma, which trades at a P/E of 54.04 and EV to EBITDA of 44.31, or NGL Fine Chem with a P/E of 39.87 and EV to EBITDA of 25.22. These comparisons highlight Anuh Pharma’s relative affordability within the sector, which could attract value-conscious investors seeking exposure to pharmaceuticals.

Peer Comparison Highlights Relative Value

When benchmarked against key competitors, Anuh Pharma’s valuation metrics stand out for their relative moderation. Bliss GVS Pharma, for instance, holds a P/E of 21.34 and an EV to EBITDA of 15.72, both higher than Anuh Pharma’s respective multiples. Similarly, Kwality Pharma’s P/E of 25.63 and EV to EBITDA of 14.62 place it in a more expensive category. This peer context underscores Anuh Pharma’s repositioning as an attractive option within the mid-tier valuation spectrum.

However, it is important to note that some companies like TTK Healthcare, despite having an attractive valuation grade, trade at a slightly higher P/E of 18.59 but with a notably elevated EV to EBITDA of 26.85, reflecting different operational and growth dynamics. This diversity within the sector suggests that investors should consider both valuation and underlying business quality when assessing opportunities.

Financial Performance and Returns: A Mixed Picture

Beyond valuation, Anuh Pharma’s financial metrics provide additional context for its investment appeal. The company’s return on capital employed (ROCE) is a healthy 14.43%, while return on equity (ROE) stands at 12.79%, indicating efficient capital utilisation and reasonable profitability. The dividend yield of 2.04% adds an income component, which may appeal to yield-seeking investors in a sector often characterised by growth-oriented stocks.

Despite these positives, the stock’s recent price performance has been volatile. Over the past week, Anuh Pharma’s share price declined by 9.28%, significantly underperforming the Sensex, which was flat at 0.02%. Year-to-date, the stock is down 8.67%, while the Sensex has fallen by 2.26%. Over a one-year horizon, the stock has declined 9.82%, contrasting with the Sensex’s robust 10.60% gain. Longer-term returns over three years remain strong at 74.17%, outperforming the Sensex’s 39.74%, though five- and ten-year returns lag the broader market.

Market Capitalisation and Mojo Score Insights

Anuh Pharma’s market capitalisation grade is rated 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 37.0, which corresponds to a Sell rating, albeit an improvement from a previous Strong Sell grade as of 4 Feb 2026. This upgrade signals a modest enhancement in the company’s overall quality and market perception, though it remains below the threshold for a Hold or Buy recommendation.

The downgrade in the Mojo Grade from Strong Sell to Sell suggests that while valuation has become more attractive, other factors such as earnings momentum, risk profile, or sector headwinds may still weigh on investor sentiment. This nuanced rating underscores the importance of a comprehensive analysis beyond valuation multiples alone.

Price Movement and Trading Range

On 24 Feb 2026, Anuh Pharma’s stock closed at ₹73.50, down 2.14% from the previous close of ₹75.11. The intraday trading range was relatively narrow, with a low of ₹73.35 and a high of ₹75.13. The stock’s 52-week high remains at ₹115.00, while the 52-week low is ₹68.00, indicating that the current price is closer to the lower end of its annual range. This proximity to the 52-week low may be a factor in the improved valuation attractiveness, as the market appears to be pricing in near-term challenges or uncertainties.

Sector Outlook and Investment Considerations

The Pharmaceuticals & Biotechnology sector continues to face a complex environment marked by regulatory scrutiny, pricing pressures, and evolving innovation cycles. Within this context, Anuh Pharma’s improved valuation metrics offer a compelling entry point for investors who prioritise value and capital efficiency. However, the company’s relative underperformance against the Sensex over recent periods and its Sell Mojo Grade caution against overly optimistic expectations.

Investors should weigh Anuh Pharma’s attractive valuation against its operational risks and sector dynamics. The company’s solid ROCE and ROE figures provide some reassurance of underlying business quality, but the stock’s recent price volatility and peer comparisons suggest that a cautious approach is warranted.

Conclusion: Valuation Improvement Offers Opportunity Amid Caution

Anuh Pharma Ltd’s recent shift in valuation parameters from fair to attractive marks a significant development for investors monitoring the Pharmaceuticals & Biotechnology sector. The company’s P/E ratio of 17.61 and P/BV of 2.25 position it as a relatively undervalued stock compared to many peers, potentially offering a value entry point. Its solid returns on capital and equity further bolster its investment case.

Nevertheless, the stock’s recent price underperformance relative to the Sensex and its current Sell Mojo Grade highlight ongoing risks and uncertainties. Investors should carefully balance the improved valuation against these factors and consider broader sector trends before committing capital.

For those seeking exposure to pharmaceuticals with a focus on valuation and capital efficiency, Anuh Pharma presents an intriguing proposition. However, a diversified approach and consideration of alternative stocks within the sector may enhance portfolio resilience and returns.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today